XORTX Corp (XRTX) - מקדם חוב לטווח ארוך להון

XORTX Therapeutics Inc. (XRTX) collaborates closely with medical centers, studying kidney pathologies to develop effective therapies. The business relies on unique uric acid modulation, offering innovative treatment for polycystic kidney disease through metabolic control. The company is currently scaling programs for the use of modified oxypurinol, and the indicator stands at 0.00. The asset's price action shown below reflects the implementation of this strategic plan.

A fundamental stress test of the position requires an analysis of the balance sheet's resilience to long-term liabilities. XORTX Therapeutics Inc. (XRTX) is developing through venture capital, focusing on clinical trials for kidney drugs. This long-term financial leverage ratio compares loans with a maturity of more than one year against net assets. An increase in this indicator signals a rising debt load relative to equity, which allows for an assessment of the business's real credit risk.